Eli Lilly looks to ease shareholders' concerns: Zyprexa questions persist at annual investor meeting

It hasn't been easy the last few years to be a shareholder of Eli Lilly and Co. Lilly's stock price has languished as the company's vaunted drug pipeline has suffered hiccups and as legal troubles over its best-selling drug, Zyprexa, have lingered. So as Lilly shareholders gather April 16 for their annual meeting, two key questions hang in the air. Both center on Zyprexa, an anti-schizophrenia drug, which accounts for one-quarter of Lilly's revenue and even more of its profit....

 

You have accessed IBJ.com Premium online content

IBJ.com Premium online content is identified by locked premium or unlocked premium symbol to the right of the headline. Access to all IBj.com Premium online content requires a paid IBJ.com Premium subscription and the subscriber to be logged in using their email and password. See subscription options below.

Log In if you are a subscriber to IBJ.com Premium Online

...Or choose the IBJ subscription that's right for you:

7 Day Subscription

$4.95 per week

IBJ.com
Premium online

Order Now
   

1 Year Subscription

$1.25 per week

IBJ.com
Premium online

Order Now
 

1 Year Subscription

$1.52 per week

IBJ Print
only

Order Now

 

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT